• Chronic kidney disease (CKD) is a major public health problem worldwide.
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• A 2008 systematic review of 26 studies conducted worldwide reported increased prevalence, with estimates from 1.5% to 43.3%; median estimates were 7.2% in persons aged 30 years and older and 23.4% to 35.8% in persons 64 years and older.
• The trend of increased prevalence across countries highlights persistent growth of CKD worldwide ( Figure 1 ).
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• As CKD becomes more complex due to comorbid illness and complications, severity of disease also increases, placing signifi cant burden on patients and health care systems. • Clearly defi ned stages of CKD and differences between early and late stages are critical for interpretation of data associated with CKD burden.
• The fi ve stages of CKD are characterized by gradual and sustained decline in glomerular fi ltration rate (GFR) function over time (Table 1) .
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• During early stage CKD, screening, risk reduction, and treatment of comorbidities are recommended to delay progression and avoid further complications of disease.
• To date, the scientifi c literature does not present the progressive burden associated with predialysis CKD for patients and health care systems. 
CKD Stage

US Dollars
Medical payments = inpatient, outpatient, and prescription drugs.
Source: Adapted from Taylor et al., 2011.
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Economic Burden of CKD
Resource Utilization and Costs of CKD
• Resource utilization and costs to health care systems and employers increase with CKD severity.
-Twelve to 24 months before dialysis initiation, costs increase substantially due to hospitalization. 4, 6, 8, 19, 20, [26] [27] [28] [29] [30] -In a 2005 inpatient Medicare claims cohort with CKD, the highest mean annual number of days hospitalized (9.51 days) was in patients with CKD. The mean annual number of physician visits in patients with CKD was second only to cancer, with 10.28 visits.
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-Mean number of physician visits increase by CKD stage (Figure 3 ).
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-Annual US total cost per patient with CKD (across stages) ranged from $1,183 to $35,292. 5, 18, 22, 26, 28, 29, [33] [34] [35] [36] -Annual total cost per non-US patient with CKD (across stages) (only available in Canada and Germany) ranged from €2,926 to €23,455. 4, 6, 24 • The cost burden of CKD is rising.
-The Medicare costs attributable to patients with CKD increased nearly fourfold from 1993 to 2008 (CKD was 3.8% of 1993 Medicare costs, and 14.2% of Medicare costs).
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• To elucidate the patient and economic burden associated with CKD worldwide.
• Targeted • Articles were selected if they reported any of the following:
-CKD staging from early to advanced disease -Change in PROs (e.g., health-related quality of life [HRQOL]) in one or more countries -Change in economics (e.g., resource utilization and cost) in one or more countries
• North American, European, and Asian studies were identifi ed; most reports were from the United States (US).
• Thirty-six articles were selected for inclusion in this review; of those, 27 were from the US.
• As CKD progresses from one stage to the next, outcomes are adversely affected.
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• With deterioration of patient health status, resource utilization and costs escalate irrespective of country. [4] [5] [6] 8, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Patient Burden of CKD
• Patients with CKD report cognitive impairment, dementia, sleep disturbance, and emotional and physical dysfunction, with physical dysfunction being most pervasive.
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• Compared with general populations, HRQOL and other PROs decline in patients with CKD. 13, 14, 16 • Age, female sex, less education, lower income, unemployment, limited exercise, and comorbid illness are predictors of reduced HRQOL. 11, 13, 15 • Progression of CKD adversely affects HRQOL. Across studies, the magnitude of physical health reduction (change from early to later stage CKD) was prominent (Figure 2) . 13, 15, 17 • Economic burden for CKD is high.
• While costs are measured differently across countries, the trend for increased resource utilization and cost burden is apparent.
• Costs increase with CKD disease progression, and hospitalizations consistently drive cost.
• As evidenced by the high cost burden, early screening, and predialysis, management of disease progression and comborbid illness are critical; whereas, disease progression may be delayed and future cost burden reduced.
Burden to Employers
• High health care costs and reduced productivity due to CKD burdens employers. 21, 23, 35 • For employees with CKD (US), health care costs range from $1,187 (€971) (Stage 3) to $21,826 (€17,846) (Stage 5) (Figure 4) , and work hours missed per week often exceeds 10.
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• Of note, a signifi cant comorbid condition, anemia, impacts direct and indirect costs from an employer perspective. • Published economic and patient-reported CKD data are sparse, with the fewest publications identifi ed in the European Union.
• CKD prevalence is increasing worldwide, thereby, placing burden on patients and health care systems.
• With disease progression (reduced kidney function), comorbid illness, and complications, unfavorable outcomes arise.
• Patient burden is increased with progression of CKD.
• Resource utilization increases with CKD progression, resulting in increased total per-patient health care expenditures across countries.
• As evidenced by the high patient and economic burden of CKD, a large unmet need exists for new therapies and employee CKD-management programs.
Please see handout for a complete reference list.
